Literature DB >> 29653956

Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

Reem A Mustafa1, Alan S L Yu2.   

Abstract

Entities:  

Keywords:  ADPKD; Autosomal Dominant; Benzazepines; Biological Phenomena; Chronic; Cysts; Humans; Kidney Failure; Polycystic Kidney; Tolvaptan; United States; Urinary Tract Physiological Phenomena; chronic kidney disease; clinical trial

Year:  2018        PMID： 29653956      PMCID： PMC6032588          DOI： 10.2215/CJN.00190118

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

2.  The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Annick Rousseau; Maryvonne Hourmant; Eric Renaudineau; Christophe Charasse; Marie-Pascale Morin; Marie-Christine Moal; Jacques Dantal; Bassem Wehbe; Régine Perrichot; Thierry Frouget; Cécile Vigneau; Jérôme Potier; Philippe Jousset; Marie-Paule Guillodo; Pascale Siohan; Nazim Terki; Théophile Sawadogo; Didier Legrand; Victorio Menoyo-Calonge; Seddik Benarbia; Dominique Besnier; Hélène Longuet; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2015-07-06       Impact factor: 10.121

3.  Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Ann Dandurand; John Ouyang; Frank S Czerwiec; Jaime D Blais
Journal:  Nephrol Dial Transplant       Date:  2017-07-01       Impact factor: 5.992

4.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Authors:  María V Irazabal; Laureano J Rangel; Eric J Bergstralh; Sara L Osborn; Amber J Harmon; Jamie L Sundsbak; Kyongtae T Bae; Arlene B Chapman; Jared J Grantham; Michal Mrug; Marie C Hogan; Ziad M El-Zoghby; Peter C Harris; Bradley J Erickson; Bernard F King; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

5.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Volume progression in polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres; Arlene B Chapman; Lisa M Guay-Woodford; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Deborah A Baumgarten; Phillip J Kenney; Peter C Harris; Saulo Klahr; William M Bennett; Gladys N Hirschman; Catherine M Meyers; Xiaoling Zhang; Fang Zhu; John P Miller
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

7.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245

9.  Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.

Authors:  Maria V Irazabal; Jaime D Blais; Ronald D Perrone; Ron T Gansevoort; Arlene B Chapman; Olivier Devuyst; Eiji Higashihara; Peter C Harris; Wen Zhou; John Ouyang; Frank S Czerwiec; Vicente E Torres
Journal:  Kidney Int Rep       Date:  2016-08-06

10.  Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Authors:  Emilie Cornec-Le Gall; Jaime D Blais; Maria V Irazabal; Olivier Devuyst; Ron T Gansevoort; Ron D Perrone; Arlene B Chapman; Frank S Czerwiec; John Ouyang; Christina M Heyer; Sarah R Senum; Yannick Le Meur; Vicente E Torres; Peter C Harris
Journal:  Nephrol Dial Transplant       Date:  2018-04-01       Impact factor: 5.992
  10 in total
  5 in total

1.  1-Indanone retards cyst development in ADPKD mouse model by stabilizing tubulin and down-regulating anterograde transport of cilia.

Authors:  Xiao-Wei Li; Jian-Hua Ran; Hong Zhou; Jin-Zhao He; Zhi-Wei Qiu; Shu-Yuan Wang; Meng-Na Wu; Shuai Zhu; Yong-Pan An; Ang Ma; Min Li; Ya-Zhu Quan; Nan-Nan Li; Chao-Qun Ren; Bao-Xue Yang
Journal:  Acta Pharmacol Sin       Date:  2022-07-29       Impact factor: 7.169

Review 2.  Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

3.  Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD.

Authors:  Andrew J Mallett; Ronald D Perrone; Gopala Rangan; Carmel Hawley; Ragada El-Damanawi; Thomas F Hiemstra; Carolina Townsend Arellano; Jennifer Lee; Vicente E Torres
Journal:  Kidney Int Rep       Date:  2021-02-02

Review 4.  Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.

Authors:  Rhubaniya Mahendran; Soo Kun Lim; Kien Chai Ong; Kek Heng Chua; Hwa Chia Chai
Journal:  Clin Exp Nephrol       Date:  2021-07-12       Impact factor: 2.801

Review 5.  Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.

Authors:  Niloofar Nobakht; Ramy M Hanna; Maha Al-Baghdadi; Khalid Mohammed Ameen; Farid Arman; Ehsan Nobahkt; Mohammad Kamgar; Anjay Rastogi
Journal:  Kidney Med       Date:  2020-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.